Literature DB >> 18695713

Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis.

Dafna D Gladman1.   

Abstract

Entities:  

Year:  2008        PMID： 18695713     DOI： 10.1038/ncprheum0880

Source DB:  PubMed          Journal:  Nat Clin Pract Rheumatol        ISSN： 1745-8382


× No keyword cloud information.
  10 in total

1.  Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability.

Authors:  Mohammad Fallahi-Sichani; JoAnne L Flynn; Jennifer J Linderman; Denise E Kirschner
Journal:  J Immunol       Date:  2012-02-29       Impact factor: 5.422

Review 2.  Psoriatic arthritis under a proteomic spotlight: application of novel technologies to advance diagnosis and management.

Authors:  Aisha Q Butt; Angela McArdle; David S Gibson; Oliver FitzGerald; Stephen R Pennington
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

Review 3.  Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs.

Authors:  Angela McArdle; Stephen Pennington; Oliver FitzGerald
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

4.  Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.

Authors:  Mariangela Atteno; Rosario Peluso; Luisa Costa; Stefania Padula; Salvatore Iervolino; Francesco Caso; Alessandro Sanduzzi; Ennio Lubrano; Antonio Del Puente; Raffaele Scarpa
Journal:  Clin Rheumatol       Date:  2010-04       Impact factor: 2.980

Review 5.  Biological therapies for spondyloarthritis.

Authors:  Vincenzo Bruner; Mariangela Atteno; Angelo Spanò; Raffaele Scarpa; Rosario Peluso
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-06       Impact factor: 5.346

6.  The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study.

Authors:  Raffaele Scarpa; Mariangela Atteno; Ennio Lubrano; Giuseppe Provenzano; Salvatore D'Angelo; Antonio Spadaro; Luisa Costa; Ignazio Olivieri
Journal:  Clin Rheumatol       Date:  2011-03-01       Impact factor: 2.980

Review 7.  Spondyloarthritides: evolving therapies.

Authors:  Andrew Barr; Andrew Keat
Journal:  Arthritis Res Ther       Date:  2010-12-17       Impact factor: 5.156

8.  Clinical and Contrast-Enhanced Ultrasound Echography Outcomes in Psoriatic Arthritis Patients after One Year of Continuous Therapy with Anti-TNF Drugs.

Authors:  Claudio Bonifati; Fulvia Elia; Dario Graceffa; Fabrizio Ceralli; Elisa Maiani; Carlo De Mutiis; Francesco M Solivetti
Journal:  ISRN Dermatol       Date:  2014-02-06

Review 9.  Efficacy and safety of adalimumab in ankylosing spondylitis.

Authors:  Aziza Mounach; Abdellah El Maghraoui
Journal:  Open Access Rheumatol       Date:  2014-08-13

Review 10.  Molecular decoys: antidotes, therapeutics and immunomodulators.

Authors:  Jonathan M Gershoni
Journal:  Curr Opin Biotechnol       Date:  2008-11-18       Impact factor: 9.740
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.